CN115895961A

CN115895961A - Blood pressure lowering probiotic powder and application thereof

Info

Publication number: CN115895961A
Application number: CN202211477926.0A
Authority: CN
Inventors: 杨希立; 陈涛
Original assignee: Guangdong Longsee Medical Technology Co ltd
Current assignee: Guangdong Longsee Medical Technology Co ltd
Priority date: 2022-11-23
Filing date: 2022-11-23
Publication date: 2023-04-04
Anticipated expiration: 2042-11-23
Also published as: CN115895961B

Abstract

The invention discloses probiotic powder for reducing blood pressure and application thereof. Belongs to the technical field of food. The probiotic powder comprises Lactobacillus rhamnosus, lactobacillus fermentum, lactobacillus acidophilus, bifidobacterium longum, lactobacillus casei, bifidobacterium animalis, bifidobacterium bifidum and Lactobacillus plantarum. After the probiotic powder is adopted to intervene in a hypertension model rat for 6 weeks, the blood pressure is obviously reduced and is close to the blood pressure level of a positive drug control group; the average of total bilirubin and direct bilirubin is obviously reduced to be equivalent to the level of normal rats; urea nitrogen and inosine rose to normal rat levels.

Description

Blood pressure lowering probiotic powder and application thereof

Technical Field

The invention relates to the technical field of food, in particular to probiotic powder for reducing blood pressure and application thereof.

Background

Hypertension is of great interest because of its "high incidence, high disability rate, high mortality rate, and low awareness rate" and its serious damage to target organs such as heart, brain, and kidney. Hypertension is one of the most common chronic diseases, can cause dysfunction of important tissues and organ structures such as heart, brain, kidney, blood vessel and the like, and is the most main risk factor of malignant cardiovascular and cerebrovascular events such as stroke, myocardial infarction, heart failure and the like.

Hypertension can be classified into secondary hypertension and primary hypertension according to pathogenesis. The pathogenesis of the secondary hypertension is clear, and the secondary hypertension accounts for less than 10% of that of patients with the secondary hypertension. Essential hypertension is also called as hypertension, and the number of patients exceeds 90% of hypertension population. The pathogenic mechanism of essential hypertension is very complex and still unclear. Previous studies have shown that the occurrence of essential hypertension is associated with a dysregulation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system.

At present, hypertension is mainly treated by medicaments, and antihypertensive medicaments comprise more than 5 types of 60 types including Calcium Channel Blockers (CCB), angiotensin Converting Enzyme Inhibitors (ACEI), diuretics, receptor blockers and angiotensin II receptor Antagonists (ARB), but still have the problems of easy generation of drug resistance, large adverse drug reactions, low treatment rate and standard reaching rate of patients, and significant increase of the incidence rate of lung cancer of patients due to long-term use of ACEI antihypertensive medicaments. In addition, most patients with hypertension require two or more hypotensives to effectively reduce blood pressure, and many patients cannot effectively control blood pressure even so. Therefore, in the face of these problems, much research on the onset of hypertension and the mechanism of action of antihypertensive drugs is urgently needed to search for new and safe drug treatment regimens and strategies.

Human intestinal tracts contain a large number of microbial communities mainly composed of bacteria, which keep a symbiotic relationship with a host and play a construction role in maintaining the metabolic balance in the host. Scientific research leads people to have deeper understanding on how the intestinal flora promotes the human health or influences the disease development, and enlarges the understanding that the composition and the function of the microorganisms influence human hosts.

Recent studies have shown that high fat diets can cause gut dysbiosis that can exacerbate the development of cardiovascular disease by affecting atherosclerosis and hypertension, thereby reducing gut integrity. Moreover, some metabolites produced by intestinal microorganisms are closely related to diseases such as chronic kidney disease, obesity, and diabetes. Such studies have shown that the intestinal microbiota functions like the endocrine organs of the human body and that the produced metabolites may directly or indirectly affect the physiological activities of the host. Therefore, the development of the composite probiotic powder with obvious intervention effect on hypertension has important practical application value.

The probiotics are used as a scavenger of intestinal tracts, and various nutrient substances are reasonably prepared for people from the intestinal tracts of a main nutrient absorption source to clean garbage in the body. After a human body eats food, the nutrient substances generally pass through the following processes: intestinal digestion and absorption, liver detoxification, blood circulation and absorption of various organs. Therefore, the intestinal tract is the first pass of food entering the human body, and the probiotics in the intestinal tract plays a role in patrol.

Probiotics regulate blood pressure mainly by the following routes: 1. hydrolysis by extracellular protease, peptidase (carboxypeptidase, nitrogen peptidase), including inhibitory peptides having angiotensin converting enzyme inhibitory activity; 2. thallus components, such as lactobacillus cell wall components, show blood pressure lowering effect in rats with essential hypertension and patients with hypertension; 3. the probiotics reach the intestinal tract in a live bacterial form, and the absorption of part of minerals capable of regulating blood pressure by the body is promoted; 4. the extracellular polysaccharide produced by part of the probiotics may have a certain antihypertensive effect.

The functionality of probiotic products has become a hot spot of research at home and abroad at present, but the attention of researchers is only drawn in the last ten years about the function of reducing blood pressure, and the clinical research on the function of reducing blood pressure of probiotic products is very short.

In conclusion, how to provide the probiotic powder for reducing blood pressure and the application thereof are problems which need to be solved urgently by the technical personnel in the field.

Disclosure of Invention

In view of the above, the invention provides a probiotic powder for reducing blood pressure and an application thereof. The probiotic powder has obvious effect of reducing blood pressure and no toxic or side effect.

In order to achieve the purpose, the invention adopts the following technical scheme:

the probiotic powder for reducing blood pressure comprises the following components in parts by weight: 1-10 parts of lactobacillus rhamnosus, 1-10 parts of lactobacillus fermentum, 1-10 parts of lactobacillus acidophilus, 1-10 parts of bifidobacterium longum, 1-10 parts of lactobacillus casei, 1-10 parts of bifidobacterium animalis, 1-10 parts of bifidobacterium bifidum and 1-10 parts of lactobacillus plantarum;

the Lactobacillus plantarum is Lactobacillus plantarum NX-1 with the preservation number of CGMCC No.20109, is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, china academy of sciences, china institute of sciences, no. 3, north Chen West Lu No. 1, anthrix, beijing, and Inward, and the preservation date is 2020, 06, 19 days, and is named as Lactobacillus plantarum in classification.

The Lactobacillus rhamnosus is Lactobacillus rhamnosus NX-2 with the preservation number of CGMCC No.20110, is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, is called CGMCC for short, is deposited at the institute of microbiology, china academy of sciences, no. 3, west Lu 1 institute of North Chen West Chen of the Yangyang area, beijing, has the preservation date of 2020, 06, 19 days and is named as Lactobacillus rhamnosus in a classification manner.

The Bifidobacterium animalis is Bifidobacterium animalis NX-6 with the preservation number of CGMCC No.20114, which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, china academy of sciences microorganism research institute No. 3, xilu No. 1, beijing, the area of the south Korean province, the preservation date is 2020, 06, 19 days, and the Bifidobacterium animalis is classified and named.

The Lactobacillus fermentum is Lactobacillus fermentum E15 with the preservation number of CGMCC No.21772, which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, and the institute of microbiology, china academy of sciences, no. 3, north West Lu 1, kyoho, beijing, with the preservation date of 2021 year, 01 month, 29 days, and is named as Lactobacillus fermentum by classification.

The Lactobacillus acidophilus is Lactobacillus acidophilus LA-03 with the preservation number of CGMCC No.22239, which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, china academy of sciences, china institute of sciences, no. 3, west Lu 1, north Cheng, south China, having the preservation date of 2021 year, 04 month and 25 days, and is classified and named as Lactobacillus acidophilus.

The Bifidobacterium longum is Bifidobacterium longum NX-8 with the preservation number of CGMCC No.20116, which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, china academy of sciences, china institute of sciences, no. 3, west Lu No. 1, north Cheng, ind, beijing, the preservation date is 2020, 06, 19 days, and is named as Bifidobacterium longum in a classified manner.

The Lactobacillus casei is Lactobacillus casei LS02 with the preservation number of CGMCC No.22007, which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, china academy of sciences, china institute of sciences, no. 3, north West Lu 1, north Cheng, chaoyang, beijing, the preservation date of 2021 year, 03 month and 15 days, and is named as Lactobacillus casei by classification.

The Bifidobacterium bifidum is Bifidobacterium bifidum NX-7 with the preservation number of CGMCC No.20115, which is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, CGMCC for short, china academy of sciences, china institute of sciences, no. 3, west Lu No. 1, north Cheng, south China, the Beijing city, the preservation date is 2020, 06, 19 days, and the Bifidobacterium bifidum is named as Bifidobacterium bifidum in a classified manner.

The beneficial effects are as follows: the lactobacillus plantarum has a plurality of health-care functions, such as 1, and has a certain immunoregulation function; 2. reducing cholesterol levels and preventing cardiovascular disease; 3. maintaining intestinal flora balance; 4. promoting the absorption of nutrient substances, especially the absorption of partial minerals capable of regulating blood pressure, etc. The lactobacillus rhamnosus NX-2 can improve the barrier capability of intestinal mucosa of a host, regulate the structure of intestinal flora and improve the immunity of organisms. The bifidobacterium animalis NX-6 can regulate the flora structure of the intestinal tract by inhibiting the growth of putrefying bacteria, can synthesize vitamins B1, B2, B6, K and the like in the intestinal tract to supplement nutrient components required by a human body, can inhibit the synthesis of cholesterol, accelerate the metabolism of the cholesterol, reduce the cholesterol level of the body and further reduce the blood pressure level of the body.

Further, the probiotic powder for reducing blood pressure comprises the following components in parts by weight: lactobacillus rhamnosus NX-25 parts, lactobacillus fermentum 5 parts, lactobacillus acidophilus 5 parts, bifidobacterium longum 5 parts, lactobacillus casei 5 parts, bifidobacterium animalis NX-64 parts, bifidobacterium bifidum 5 parts and lactobacillus plantarum NX-14 parts;

the lactobacillus plantarum is lactobacillus plantarum NX-1 with the preservation number of CGMCC No.20109;

the lactobacillus rhamnosus is lactobacillus rhamnosus NX-2 with the preservation number of CGMCC No.20110;

the lactobacillus acidophilus is lactobacillus acidophilus LA-03 with the preservation number of CGMCC No.22239;

the bifidobacterium longum is bifidobacterium longum NX-8 with the preservation number of CGMCC No.20116;

the lactobacillus casei is lactobacillus casei LS02 with the preservation number of CGMCC No.22007;

the bifidobacterium bifidum is bifidobacterium bifidum NX-7 with the preservation number of CGMCC No.20115;

the lactobacillus fermentum is lactobacillus fermentum E15 with the preservation number of CGMCC No.21772;

the bifidobacterium animalis is bifidobacterium animalis NX-6 with the preservation number of CGMCC No.20114.

The probiotic powder mainly used for reducing blood pressure comprises the following components: the hydrolysis of the probiotic extracellular protease and peptidase is utilized to release peptide fragments with the antihypertensive activity in the food protein, the peptide fragments are combined with the activity center of angiotensin converting enzyme to competitively inhibit the activity of the angiotensin converting enzyme, so that angiotensin I can not be converted into angiotensin II, and bradykinin is catalyzed to be hydrolyzed into inactive fragments, thereby playing the role of lowering blood pressure; the probiotics efficiently catalyzes decarboxylation of the L-glutamic acid to generate g-aminobutyric acid, regulates the central nervous system, acts on the vasomotor center of the spinal cord, is combined with a synaptic receptor playing a role in expanding blood vessels and a sympathetic nerve ending inhibition receptor, and effectively promotes the vasodilatation, so that the aim of reducing blood pressure is fulfilled.

The probiotic powder is applied to preparation of products for assisting blood pressure reduction.

According to the technical scheme, compared with the prior art, the invention has the following beneficial effects: after the probiotic powder is adopted to intervene in a hypertension model rat for 6 weeks, the blood pressure is obviously reduced and is close to the blood pressure level of a positive drug control group; the average of total bilirubin and direct bilirubin is obviously reduced to be equivalent to the level of normal rats; urea nitrogen and inosine rose to normal rat levels.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the embodiments or the prior art descriptions will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.

FIG. 1 is a graph showing the blood pressure results in experiment 1 of the present invention, wherein A is the diastolic blood pressure (SBP) result of a rat, B is the systolic blood pressure (DBP) result of a rat, C is the Mean Blood Pressure (MBP) result of a rat, and D is the Heart Rate (HR) result of a rat;

FIG. 2 is a diagram showing the biochemical analysis results of blood pathology in experiment 1, wherein A is the results of Total Bilirubin (TBIL) in rat serum, B is the results of Direct Bilirubin (DBIL) in rat serum, C is the results of urea nitrogen (BUN) in rat serum, D is the results of inosine (CR) in rat serum, and E is the results of Uric Acid (UA) in rat serum;

FIG. 3 is a graph showing the results of pathological analysis of aorta and kidney in experiment 1 according to the present invention;

FIG. 4 is a histogram of the distribution of LEfSe LDA values for the differences in the intestinal flora of three groups of rats in experiment 1 according to the present invention;

FIG. 5 is a LEfSe cladogram used to analyze the differences in intestinal flora of three groups of rats in experiment 1.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.

The unrecited experimental method is a conventional experimental method, and is not described in detail herein.

Example 1

Lactobacillus rhamnosus NX-2 (0.001 g), lactobacillus fermentum E15 (0.010 g), lactobacillus acidophilus LA-03 (0.010 g), bifidobacterium longum NX-8 (0.003 g), lactobacillus casei LS02 (0.005 g), bifidobacterium animalis NX-6 (0.001 g), bifidobacterium bifidum NX-7 (0.006 g) and lactobacillus plantarum NX-1 (0.001 g).

Example 2

Lactobacillus rhamnosus NX-2 (0.009 g), lactobacillus fermentum E15 (0.001 g), lactobacillus acidophilus LA-03 (0.001 g), bifidobacterium longum NX-8 (0.002 g), lactobacillus casei LS02 (0.007 g), bifidobacterium animalis NX-6 (0.008 g), bifidobacterium bifidum NX-7 (0.001 g), lactobacillus plantarum NX-1 (0.008 g).

Example 3

Lactobacillus rhamnosus NX-2 (0.005 g), lactobacillus fermentum E15 (0.005 g), lactobacillus acidophilus LA-03 (0.005 g), bifidobacterium longum NX-8 (0.005 g), lactobacillus casei LS02 (0.004 g), bifidobacterium animalis NX-6 (0.004 g), bifidobacterium bifidum NX-7 (0.005 g) and lactobacillus plantarum NX-1 (0.004 g).

Experiment 1

Experimental methods

1. Operation preparation of two-kidney one-clamp (2K 1C) renal hypertension rat model

1. Animals: SD rat (male), weighing 220g; the rats are fasted without water prohibition 12 hours before the operation;

2. as the intestinal flora analysis is carried out, an inhalation anesthesia mode is selected;

3. longitudinally cutting a 1.5cm incision on the left back of a rat in an operation, separating the left renal artery, and placing a silver clip to constrict the blood vessel;

4. dripping a small amount of penicillin, and suturing the incision;

5. after the blood pressure rises steadily, measuring the blood pressure value of the rat, and keeping the animal model with the systolic pressure more than 21.3 kpa.

2. Experimental groups (10 rats per group)

1. Control group (PBS): modeling a rat, and perfusing a PBS solution with the same volume as the stomach without medicine intervention;

2. complex probiotic group (Probiotics): gavage the probiotic powder prepared in example 3 of the invention;

3. positive drug control group (Positive): and (4) performing intragastric administration on the losartan.

3. Pharmaceutical intervention

1. The administration amount of the composite probiotic group is 0.037 g/probiotic;

2. the dosage of the positive drug control group is 0.06 mg/mouse;

3. the control group was gavaged with an equal amount of PBS;

once daily, intervention was performed for 6 weeks.

4. Animal experiment observation record

1. Drug dry expect, rat body weights were recorded every 1 week;

2. observing and recording the living state of the rat;

3. rat blood pressure was recorded every 1 week.

5. Drawing after the intervention experiment

1. Collecting peripheral blood of rat, standing at room temperature for 30min, centrifuging at 1000rpm/min, centrifuging for 10min, collecting supernatant, and placing in refrigerator at-80 deg.C for use.

2. Collecting kidney tissue and abdominal aorta tissue, cleaning with normal saline, adsorbing blood with test paper, and placing in 4% paraformaldehyde.

3. The cecal contents and feces were taken.

6. Detecting the index

1. Analyzing serum Total Bilirubin (TBIL), serum Direct Bilirubin (DBIL), serum urea nitrogen (BUN), serum inosine (CR) and blood Uric Acid (UA);

2. staining kidney and abdominal aorta tissue sections;

3. cecal contents and feces were collected for analysis of intestinal flora composition and metabolites.

Test method

(1) Biochemical analysis of blood pathology

Serum Total Bilirubin (TBIL), serum Direct Bilirubin (DBIL), serum urea nitrogen (BUN), serum inosine (CR) and serum Uric Acid (UA) in serum are detected by using a full-automatic biochemical analyzer.

(2) Tissue section

1. Evaluation of renal structure reparability: kidney tissue was fixed with 4% paraformaldehyde for 24h. Sections of tissue were paraffin embedded, sections 4 μm thick, and sections stained with hematoxylin and eosin (H & E). The renal structure was observed under a microscope.

2. Pathological assessment of atherosclerotic lesions of the abdominal aorta: the aortic arch is continuously sliced (4 μm), and the pathological characteristics of the plaque cross section are observed by hematoxylin-eosin (HE) staining.

(3) Rat intestinal flora structure after 16S rRNA sequencing identification intervention

1.16S rRNA sequencing: primers were designed around conserved regions around the V3-V4 region and the flora V3-V4 region was amplified using Phusion enzymes. After one round of amplification, different adapters and barcodes are added to the two ends of the positive and negative primers respectively, and then the next round of amplification is carried out. And (3) after the amplified PCR product is purified, constructing an Illumiina sequencing library, and performing computer sequencing.

2. Bioinformatics analysis: analyzing Illumina Miseq sequencing data, firstly, merge splicing double-end data obtained by Miseq sequencing into tag according to an Overlap relation, carrying out sample distinguishing according to Barcode information, carrying out quality control analysis such as Q20 and Q30 on the spliced data, and carrying out data filtering. Performing OUT merging and division on the finally obtained Clean data, performing ALPHA diversity analysis on the basis, evaluating the diversity level and abundance distribution of the samples, specifically forming each sample (group) at different classification levels, and checking whether the groups have statistical difference; BETA diversity analysis further measures the differences in flora structure between different samples (groups) and key species screening. And finally, predicting the flora metabolism function of each sample according to the 16S rRNA gene sequencing result.

7. Results of the experiment

The blood pressure results are shown in fig. 1, wherein PBS is a control group, positive is a Positive drug control group (losartan), and Probiotics is a complex probiotic group. The result shows that after the probiotic powder prepared by the invention intervenes in hypertensive rats for 6 weeks, the diastolic pressure (SBP), systolic pressure (DBP) and Mean Blood Pressure (MBP) of the rats are all obviously reduced to be close to the blood pressure level of the rats in a positive drug control group; the rat Heart Rate (HR) decreased.

The biochemical analysis results of blood pathology are shown in fig. 2. Compared with a control group, the serum Total Bilirubin (TBIL) and the serum Direct Bilirubin (DBIL) levels of the compound probiotic group rats are obviously reduced to be equivalent to the bilirubin levels of the positive drug control group rats; there were few changes in serum urea nitrogen, inosine, and uric acid levels in three groups of rats.

Pathological conditions of abdominal aorta and kidney tissues of three groups of rats were analyzed for dry prognosis by tissue section and HE staining. As shown in fig. 3, the abdominal aorta vessel wall of the control group is significantly thicker, the abdominal aorta intima surface of the rats of the control group and the positive drug control group is uneven, the arrangement of the media smooth muscle is disordered, and the vessel wall thickness is different; the composite probiotics group rat abdominal aorta vascular wall intima surface is smooth, complete and free of damage, the media smooth muscle is arranged in order, and the thickness is uniform, so that the probiotics group rat abdominal aorta vascular wall intima surface can not only adjust the blood pressure level of the rat, but also repair the abdominal aorta structure. The glomerular basement membrane of the rat in the control group is obviously shrunk and thickened, and segmental fibrin-like necrosis appears in a glomerular capillary loop; the glomerular sacculus gap of the control group and the positive drug control group is obviously widened, which indicates that the intrarenal cyst pressure is increased. The glomerulus of the composite probiotic group is full and has a complete structure. Indicating that the probiotic intervention can repair the structural damage of the kidney caused by the hypertension model. Structural damage to the kidneys is caused by the two-kidney one-clamp modeling process. Further enhance the fluidity of blood and relieve blood pressure.

Aiming at the characteristic analysis of high-abundance organisms and genomes, LEfSe analysis is adopted to distinguish the intestinal floras of three groups of rats, firstly, the characteristic floras with obvious abundance difference are detected, then, the floras with obvious difference from the abundance are found, and finally, the influence of the abundance of each species on the difference effect is evaluated by linear discriminant analysis. As shown in fig. 4, LEfSe LDA value distribution histogram analysis (LDA threshold of 2) revealed that there were 3 distinct flora in the control group, 18 genus upregulation in the positive drug control group, and 20 genus upregulation in the complex probiotic group. The results show that the intestinal flora structure has obvious change in the hypertension treatment process, and the flora structure change of the composite probiotic group is larger than that of the positive drug control group. Further LEfSe cladogram analysis shows (as shown in fig. 5), different from the change of the intestinal flora structure of rats in the positive drug control group, probiotic intervention can significantly up-regulate the dominant flora, such as bifidobacterium (f _ bifidobacterium), butyric acid coccus (g _ Butyricicoccus), colinss (g _ collinesella), and the like. In conclusion, intervention of probiotics on hypertensive rats can not only regulate the blood pressure level of rats, but also change the intestinal flora structure of rats, and particularly up-regulate the abundance of dominant flora.

The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.

The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. The probiotic powder for reducing blood pressure is characterized by comprising the following components in parts by weight: 1-10 parts of lactobacillus rhamnosus, 1-10 parts of lactobacillus fermentum, 1-10 parts of lactobacillus acidophilus, 1-10 parts of bifidobacterium longum, 1-10 parts of lactobacillus casei, 1-10 parts of bifidobacterium animalis, 1-10 parts of bifidobacterium bifidum and 1-10 parts of lactobacillus plantarum;

the lactobacillus rhamnosus is lactobacillus rhamnosus NX-2, and the preservation number is CGMCC No.20110;

2. The blood pressure lowering probiotic powder according to claim 1, characterized by comprising the following components in parts by weight: 5 parts of lactobacillus rhamnosus, 5 parts of lactobacillus fermentum, 5 parts of lactobacillus acidophilus, 5 parts of bifidobacterium longum, 5 parts of lactobacillus casei, 4 parts of bifidobacterium animalis, 5 parts of bifidobacterium bifidum and 4 parts of lactobacillus plantarum;

3. Use of a probiotic powder according to any of claims 1 or 2 for the preparation of a product for assisting in lowering blood pressure.